|
|
|
|
Drop in Abdominal Obesity Cuts Risk of Macular Degeneration
_ Drop in Abdominal Obesity Cuts Risk of Macular Degeneration.
|
|
|
Drop in Abdominal Obesity Cuts Risk of Macular Degeneration
_ Drop in Abdominal Obesity Cuts Risk of Macular Degeneration.
|
|
|
Documenting Fixation at an Extrafoveal Locus with a Modified Slit Lamp in Age-Related Macular Degeneration
British Journal of Ophthalmology, 10/06/08 Investigative Ophthalmology and Visua Documenting Fixation at an Extrafoveal Locus with a Modified Slit Lamp in Age-Related Macular Degeneration.
|
|
|
Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in Age-Related Macular Degeneration
Oh IK et al.- Hypertension, minimally classic lesion, advanced age and a previous hemorrhagic event were associated with the development of hemorrhage within 2 weeks after PDT. Risk Factors for Retinal Hemorrhage after Photodynamic...
|
|
|
Macular Degeneration - Studies from Kyoto University, Medical Department update current data on macular degene
Medical Devices & Surgical Technology Week Welcome to NewsRx!Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week We're a pay-per-view site for premium content! If you'd like to...
|
|
|
Macular Degeneration - Long-Term Results of VisionCare's Implantable Telescope for End-Stage Macular Degenerat
VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related degeneration (AMD), announced that the American Journal of Ophthalmology (AJO), a premier peer-reviewed medical...
|
|
|
Telik to provide new TRAP drug discovery technology to HSS investigators
Telik, Inc.announced an agreement to provide its TRAP drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms underlying musculoskeletal and autoimmune...
|
|
|
Analysis of Major Alleles Associated With Age-Related Macular Degeneration in Patients With Multifocal Choroid
About MDLinx| Contact | Advertise with MDLinx | Site Map | Privacy Policy | Terms of Use | Sign Up For Newsletters | Recommend this Site English| Espaol | Franais | Deutsch | | cc | Norsk | Nederlands | Portugus | Italiano 1999-2008 MDLinx,...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
/PRNewswire-FirstCall/ -- Telik, Inc.announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
PALO ALTO, Calif., Nov.12 /PRNewswire-FirstCall/ -- Telik, Inc. announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
PALO ALTO, Calif., Nov.12 /PRNewswire-FirstCall/ -- Telik, Inc. announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
PALO ALTO, Calif., Nov.12 /PRNewswire-FirstCall/ -- Telik, Inc. announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
PALO ALTO, Calif., Nov.12 /PRNewswire-FirstCall/ -- Telik, Inc. announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS...
|
|
|
Telik Announces New TRAP Drug Discovery Agreement
PALO ALTO, Calif., Nov.12 /PRNewswire-FirstCall/ -- Telik, Inc. announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS...
|
|
|
Flexible Dosing of Ranibizumab Safe, Maintains Efficacy in Age-Related Macular Degeneration: Presented at AAO
-- A flexible dosing schedule for ranibizumab maintains efficacy outcomes in treatment-nave patients with neovascular age-related macular degeneration (AMD), according to research presented at the American Academy of Ophthalmology (AAO...
|
|
|
Large Analysis Supports Safety of Ranibizumab in Neovascular Age-Related Macular Degeneration: Presented at AA
-- Ranibizumab appears to be safe for use in the treatment of neovascular ('wet') age-related macular degeneration (AMD), although the occurrence of sterile inflammation was evident, according to an analysis of 4 large phase 3 trials,...
|
|
|
AAO updates media on key ophthalmic issues
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo In the past year, the world of ophthalmology has seen some significant headlines.They captured numerous issues that...
|
|
|
Pegaptanib Maintains Visual Outcomes in Age-Related Macular Degeneration After Vascular Endothelial Growth Fac
-- Pegaptanib administered every 6 weeks for 1 year appears to maintain outcomes after initial vascular endothelial growth factor (VEGF) inhibition with bevacizumab or ranibizumab in patients with neovascular age-related macular...
|
|
|
AAO/SOE 2008: Ranibizumab Appears Safe for Wet Age-Related Macular Degeneration
_ AAO/SOE 2008: Ranibizumab Appears Safe for Wet Age-Related Macular Degeneration.
|
|
|
Potentia Presents Phase I Data on Leading AMD Drug at AAO
Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects ATLANTA, GA November 10,...
|
|
|
American Academy of Ophthalmology Meeting Features Advances in Research and Treatment
Today's scientific program includes reports on a potential biomarker for age-related macular degeneration (AMD) that may also imply common biological signaling mechanisms for general aging and AMD, and on positive results in...
|
|
|
Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in
AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects ATLANTA, November 10, 2008 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited , a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited , a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment...
|
